TURNSTONE BIOLOGICS CORP.

Press Releases Turnstone Biologics Corp.

Equities

TSBX

US90042W1009

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-10 pm EDT			5-day change	1st Jan Change
3.05 ^USD	+6.27%		+12.13%	+19.84%

Apr. 16	Turnstone Biologics Corp. Announces Board Changes	CI
Mar. 21	Turnstone Biologics Corp. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Turnstone Biologics to Present at the 2024 Bank of America Securities Health Care Conference	May. 08	GL
Turnstone Biologics Appoints William Waddill to its Board of Directors	Apr. 16	GL
Turnstone Biologics Corp. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Recent Business Highlights	Mar. 21	GL
Turnstone Biologics Corp. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Recent Business Highlights	Mar. 21	AQ
Turnstone Biologics to Participate in Upcoming Investor Conferences	Feb. 21	AQ
Turnstone Biologics Announces the Passing of Chief Legal Officer P. Joseph Campisi, Jr., Esq.	Feb. 20	GL
Turnstone Biologics to Participate in the Piper Sandler 35th Annual Healthcare Conference	Nov. 27	GL
Turnstone Biologics Corp. Reports Third Quarter 2023 Financial Results and Provides Recent Business Highlights	Nov. 09	GL
Turnstone Biologics Presents Preclinical Data Highlighting Potential for Selected Tumor-Infiltrating Lymphocyte (TIL) Therapy in Solid Tumors at the 2023 Society for Immunotherapy of Cancer (SITC) Annual Meeting	Nov. 03	GL
Turnstone Biologics Presents Preclinical Data Highlighting Potential for Selected Tumor-Infiltrating Lymphocyte (TIL) Therapy in Solid Tumors at the 2023 Society for Immunotherapy of Cancer (SITC) Annual Meeting	Nov. 03	AQ
Turnstone Biologics Expands Scientific Advisory Board with Appointment of Dr. Jeffrey S. Weber	23-10-30	GL
Turnstone Biologics to Present Preclinical Data for Selected Tumor-Infiltrating Lymphocyte (TIL) Therapy at Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting	23-09-28	GL
Turnstone Biologics to Present Preclinical Data for Selected Tumor-Infiltrating Lymphocyte (TIL) Therapy at Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting	23-09-28	AQ
Turnstone Biologics Corp. Reports Second Quarter 2023 Financial Results and Provides Business Update	23-09-01	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.

SIGN UP NOW